Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised contro
已完结
10
由 用户hgrOY6 发布于 2026-08-07 23:16
作者:
Vania Hungria,Marek Hus,ChengCheng Fu,Vera Zherebtsova,Christopher Ward,P Joy Ho,Damian Mikulski,Ludmila Muronova,Claudio Cerchione,Angely Loubert,Laurine Bunod,Manal M'Hari,Nick Pirooz,Rachel Rogers,
文献类型:
期刊论文
补充材料:
只需要正文
Elsevier
应助信息
2026-08-07
2026-08-07
文献港机器人
2026-08-07 23:16:45
未找到该文献,机器人已退出,请等待人工下载
2026-08-07 23:16:45
文献港机器人收到请求,开始寻找文献
2026-08-07 23:16:45
已向机器人发送请求
2026-08-07